TrialSignal
Clinical trial intelligence report
The Effects of Sativex on Neurocognitive and Behavioural Function in Adults With Attention-deficit/Hyperactivity Disorder; The EMA-C Study (Experimental Medicine in ADHD - Cannabinoids)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 17, 2026
NCT ID
NCT02249299
Status
COMPLETED
Phase
NA
Sponsor
King's College London
Executive brief
Investment-Ready Snapshot
Adult patients with ADHD commonly report an improvement in behavioural symptoms when using cannabis with some reporting a preference towards cannabis over their ADHD stimulant medication. The EMA-C study aims to investigate the effects of a cannabis based medication, Sativex Oromucosal Spray on behaviour and cognition in adults with ADHD. This will be carried out by conducting a placebo controlled trial. 30 adults with ADHD will take Sativex or a dummy medication (a placebo) every day for 6 weeks. There is a 50% chance of receiving the Sativex or Placebo. Measures of behaviour and cognition will be taken before and after 6 weeks of treatment. We hypothesise that treatment with Sativex will result in improvements in behaviour and cognition above that of the placebo group.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02249299
Indication
Attention Deficit Hyperactivity Disorder (ADHD)
Modality
small molecule
Target
Sativex Oromucosal Spray, Placebo
Intervention
Sativex Oromucosal Spray, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.